Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
225 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape. Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 14, 5, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively. Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology). - The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Systemic Sclerosis (Scleroderma) - Overview 8 Systemic Sclerosis (Scleroderma) - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 14 Products under Development by Companies 15 Products under Development by Universities/Institutes 18 Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 23 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31 Allergan Plc 31 AnaMar AB 31 Angion Biomedica Corp 32 arGentis Pharmaceuticals LLC 32 Bayer AG 33 Biogen Inc 33 BLR Bio LLC 34 Boehringer Ingelheim GmbH 34 Bristol-Myers Squibb Company 35 Covis Pharmaceuticals Inc 35 CSL Ltd 36 Cumberland Pharmaceuticals Inc 36 F. Hoffmann-La Roche Ltd 37 Fibrocell Science Inc 37 GenKyoTex SA 38 Gilead Sciences Inc 38 GlaxoSmithKline Plc 39 iBio Inc 39 Inventiva 40 Leadiant Biosciences Inc 40 MedImmune LLC 41 Patagonia Pharmaceuticals LLC 41 PDX Pharmaceuticals LLC 42 Peptinov SAS 42 ProMetic Life Sciences Inc 43 Ribomic Inc 43 Samumed LLC 44 Sanofi 44 Seattle Genetics Inc 45 Stemline Therapeutics Inc 45 Stratatech Corp 46 Vicore Pharma AB 46 viDA Therapeutics Inc 47 VivaCell Biotechnology Espana SL 47 Systemic Sclerosis (Scleroderma) - Drug Profiles 48 abatacept - Drug Profile 48 acALY-18 - Drug Profile 56 ambrisentan - Drug Profile 57 anabasum - Drug Profile 60 ANG-3070 - Drug Profile 68 ARG-201 - Drug Profile 69 belimumab - Drug Profile 71 BLR-200 - Drug Profile 78 brentuximab vedotin - Drug Profile 79 C-1889 - Drug Profile 106 C-21 - Drug Profile 108 C-82 - Drug Profile 111 Cell Therapy for Dermatology and Immunology - Drug Profile 112 CM-101 - Drug Profile 114 dimethyl fumarate DR - Drug Profile 115 elapegademase - Drug Profile 120 factor XIII (human) - Drug Profile 121 FCX-013 - Drug Profile 122 GKT-831 - Drug Profile 123 GSK-2330811 - Drug Profile 127 IBIOCFB-03 - Drug Profile 128 ifetroban sodium - Drug Profile 130 IVA-337 - Drug Profile 132 M-10 - Drug Profile 134 MEDI-7734 - Drug Profile 135 miRNA-29 - Drug Profile 136 Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 137 nintedanib - Drug Profile 138 nitroglycerin - Drug Profile 149 onabotulinumtoxinA - Drug Profile 151 PAT-048 - Drug Profile 156 PATS-03 - Drug Profile 157 PBI-4050 - Drug Profile 158 PBI-4425 - Drug Profile 166 PDX-002 - Drug Profile 167 PPV-06 - Drug Profile 168 RBM-006 - Drug Profile 169 riociguat - Drug Profile 170 rituximab biosimilar - Drug Profile 176 RP-182 - Drug Profile 177 SAR-100842 - Drug Profile 178 SAR-156597 - Drug Profile 179 SAR-317461 - Drug Profile 180 SM-04755 - Drug Profile 181 Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 183 Small Molecules to Antagonize 5-HT2B for Idiopathic Pulmonary Fibrosis and Systemic Sclerosis - Drug Profile 184 sodium nitrite SR - Drug Profile 185 Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 187 terguride - Drug Profile 188 tocilizumab - Drug Profile 189 TRX-101 - Drug Profile 199 VCE-0048 - Drug Profile 200 VEDA-1209 - Drug Profile 201 VTI-1000 Series - Drug Profile 202 Wnt-001 - Drug Profile 203 Systemic Sclerosis (Scleroderma) - Dormant Projects 204 Systemic Sclerosis (Scleroderma) - Discontinued Products 206 Systemic Sclerosis (Scleroderma) - Product Development Milestones 207 Featured News & Press Releases 207 Appendix 220 Methodology 220 Coverage 220 Secondary Research 220 Primary Research 220 Expert Panel Validation 220 Contact Us 220 Disclaimer 221
List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Leadiant Biosciences Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Seattle Genetics Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Stratatech Corp, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by Vicore Pharma AB, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H2 2017 Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H2 2017 Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017 Systemic Sclerosis (Scleroderma) - Dormant Projects, H2 2017 (Contd..1), H2 2017 Systemic Sclerosis (Scleroderma) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
